Literature DB >> 11451417

Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens.

S S Park1, C J Ryu, Y J Kang, S V Kashmiri, H J Hong.   

Abstract

Hepatitis B virus (HBV) infection is a worldwide public health problem affecting about 350 million people. HBV envelope contains three surface antigens, called pre-S1, pre-S2 and S. For the prophylaxis of HBV infection, only an anti-S monoclonal antibody was tested for the protective efficacy against HBV infection, but it was shown to be incomplete. In addition, some immune escape mutants carrying mutations on the S antigen were reported. Therefore, a multivalent bispecific antibody rather than a single monoclonal antibody would be more beneficial for the prophylaxis of HBV infection. We have generated a novel tetravalent bispecific antibody with two binding sites for each of the S and pre-S2 antigens. Each of the antigen-binding sites was composed of a single-chain Fv (ScFv). The tetravalent antibody was generated by constructing a single gene encoding a single-chain protein. This protein consisted of an anti-S ScFv whose carboxyl end was tethered, through a 45 amino acid linker, to the amino terminus of anti-preS2 ScFv that in turn was joined to the hinge region of human gamma1 constant region. The single-chain protein was expressed in Chinese hamster ovary cells and secreted in culture supernatant as a homodimeric molecule. The tetravalent bispecific antibody showed both anti-S and anti-pre-S2 binding activities. In addition, the binding affinity of the bispecific antiboy for HBV particles was greater than that of either parental antibody. The tetravalent bispecific antibody is a potentially useful reagent for the prevention and treatment of HBV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11451417     DOI: 10.1016/s0161-5890(01)00027-x

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.

Authors:  Shiyong Gong; Fang Ren; Danqing Wu; Xuan Wu; Chengbin Wu
Journal:  MAbs       Date:  2017-07-10       Impact factor: 5.857

2.  Solubility of disulfide-bonded proteins in the cytoplasm of Escherichia coli and its "oxidizing" mutant.

Authors:  Sheng Xiong; Yi-Fei Wang; Xiang-Rong Ren; Bing Li; Mei-Ying Zhang; Yong Luo; Ling Zhang; Qiu-Ling Xie; Kuan-Yuan Su
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

3.  Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.

Authors:  Zhengxing Qu; David M Goldenberg; Thomas M Cardillo; Victoria Shi; Hans J Hansen; Chien-Hsing Chang
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

Review 4.  Bispecific antibodies and their applications.

Authors:  Gaowei Fan; Zujian Wang; Mingju Hao; Jinming Li
Journal:  J Hematol Oncol       Date:  2015-12-21       Impact factor: 17.388

5.  In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy.

Authors:  Robert L Kruse; Thomas Shum; Xavier Legras; Mercedes Barzi; Frank P Pankowicz; Stephen Gottschalk; Karl-Dimiter Bissig
Journal:  Mol Ther Methods Clin Dev       Date:  2017-08-31       Impact factor: 6.698

Review 6.  Engineering Antibodies for the Treatment of Infectious Diseases.

Authors:  Gaowei Fan; Jinming Li
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.